Host endosomal entry / trafficking
MoreNasal & Oral Sprays / Rinses
MoreHost targets and pathways
MoreInflammatory and immune modulation
MoreOxidative stress and cytoprotection
MoreReplication inhibition (target unresolved)
MorePleiotropic modulation
MoreAttachment / entry inhibition
MoreNutrients and microbiome support
MoreIL-6 / IL-6R blockade
MorePhysical and extracorporeal interventions
MoreNatural products and extracts
MoreUnconfirmed antiviral rationale
MoreLifestyle, behaviors, and exposure prevention
MoreOther complication management
MoreHost pyrimidine synthesis
MoreDirect viral inactivation
MoreEndothelial / vascular protection
MoreDirect respiratory tract treatments
MoreOther antibodies, proteins, peptides, cells, and RNA therapies
MoreSecondary infection and coinfection management
More
713 patient dimethyl fumarate late treatment RCT: 3% higher mortality (p=0.89), 20% higher ventilation (p=0.65), and 12% worse 7-point scale results (p=0.41).
RCT 713 hospitalized COVID-19 patients showing no significant difference in clinical outcomes with dimethyl fumarate. 6-month results are from [Horby]
Jan 2024, Nature Communications, https://www.nature.com/articles/s41467-023-43644-x, https://c19p.org/horby14
